A phase 1/2 study of IPH5401 antibody and Imfinzi® (durvalumab) for patients with solid tumors.
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs IPH 5401 (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STELLAR-001
- Sponsors Innate Pharma
- 08 Mar 2018 According to Innate Pharma media release, company expect to start this study in 2018.
- 01 Feb 2018 New trial record